Evidence map›Paper›PMID 34934549›Full record

ArticleCureus2021

First Case of Erythema Nodosum Associated With Pfizer Vaccine.

Mohammed H Aly, Abdulrahman A Alshehri, Abdelgaffar Mohammed, Abdulrahman M Almalki, Walaa A Ahmed, Alhanouf M Almuflihi, Atheer A Alwafi

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Atypical Presentation of Erythema Nodosum Following Pfizer-BioNTech COVID-19 Vaccine.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2022
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mohammed H AlyDepartment of Internal Medicine, Security Forces Hospital, Makkah, SAU.
Abdulrahman A AlshehriDepartment of Rheumatology, Security Forces Hospital, Makkah, SAU.
Abdelgaffar MohammedDepartment of Internal Medicine, Security Forces Hospital, Makkah, SAU.
Abdulrahman M AlmalkiDepartment of Medicine, College of Medicine, Umm Al-Qura University, Al-Abdia Main Campus, Makkah, SAU.
Walaa A AhmedDepartment of Medicine, College of Medicine, Umm Al-Qura University, Al-Abdia Main Campus, Makkah, SAU.
Alhanouf M AlmuflihiDepartment of Medicine, College of Medicine, Umm Al-Qura University, Al-Abdia Main Campus, Makkah, SAU.
Atheer A AlwafiDepartment of Medicine, College of Medicine, Umm Al-Qura University, Al-Abdia Main Campus, Makkah, SAU.
Umm al-Qura University · SASecurity Forces Hospital · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccine-related erythema nodosum is uncommon, especially after the coronavirus disease 2019 (COVID-19) vaccine. This study presents the first case of the Pfizer vaccine associated with erythema nodosum. A 22-year-old healthy woman presented with a five-day history of several red painful areas with swelling in the lower extremities that started one day after receiving the first dose of Pfizer vaccine. Past medical history, laboratory investigation, and chest radiograph revealed normal results. Erythema nodosum is an immune reaction that manifests as multiple, painful nodules commonly seen on the shin that resolved spontaneously two to eight weeks after the onset. In the absence of laboratory and chest radiograph abnormalities and shortly after receiving the Pfizer vaccine, vaccine-related erythema nodosum is the only possible explanation.

Indexed as

covid-19cutaneous side effectserythema nodosumpfizervaccines

Identifiers

PMID34934549
PMCPMC8668049
OpenAlexW3212271429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.